Nuvation Bio Inc. Foreign Currency Transaction Gain (Loss), Unrealized
Nuvation Bio Inc. (NUVB) reported Foreign Currency Transaction Gain (Loss), Unrealized of $229.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ForeignCurrencyTransactionGainLossUnrealized · last filed 2026-08-06
- Nuvation Bio Inc. foreign currency transaction gain (loss), unrealized for the quarter ending 2026-06-30 was $208.00K, a 54.08% decline year-over-year.
- Nuvation Bio Inc. foreign currency transaction gain (loss), unrealized for the quarter ending 2026-03-31 was $21.00K.
- Nuvation Bio Inc. foreign currency transaction gain (loss), unrealized for the quarter ending 2025-12-31 was $670.00K.
- Nuvation Bio Inc. foreign currency transaction gain (loss), unrealized for the quarter ending 2025-09-30 was $210.00K.
- Nuvation Bio Inc. foreign currency transaction gain (loss), unrealized for fiscal 2025 was $1.08M.
- Nuvation Bio Inc. foreign currency transaction gain (loss), unrealized for fiscal 2024 was $0.00.
| Period end | Foreign Currency Transaction Gain (Loss), Unrealized 3 month | Foreign Currency Transaction Gain (Loss), Unrealized 6 month | Foreign Currency Transaction Gain (Loss), Unrealized 9 month | Foreign Currency Transaction Gain (Loss), Unrealized 12 month |
|---|---|---|---|---|
| 2026-06-30 | $208.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $229.00K 10-Q · filed 2026-08-06 | $899.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.11M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $21.00K 10-Q · filed 2026-05-04 | $691.00K derived: sum of 2 quarters · filed 2026-05-04 | $901.00K derived: sum of 3 quarters · filed 2026-05-04 | $1.35M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $670.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $880.00K derived: sum of 2 quarters · filed 2026-03-02 | $1.33M derived: sum of 3 quarters · filed 2026-08-06 | $1.08M 10-K · filed 2026-03-02 |
| 2025-09-30 | $210.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $663.00K derived: sum of 2 quarters · filed 2026-08-06 | $415.00K 10-Q · filed 2025-11-03 | $415.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $453.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $205.00K 10-Q · filed 2026-08-06 | $205.00K derived: sum of 3 quarters · filed 2026-08-06 | $205.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$248.00K 10-Q · filed 2026-05-04 | -$248.00K derived: sum of 2 quarters · filed 2026-05-04 | -$248.00K derived: sum of 3 quarters · filed 2026-05-04 | -$248.00K derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $0.00 derived: sum of 3 quarters · filed 2026-03-02 | $0.00 10-K · filed 2026-03-02 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $0.00 derived: sum of 2 quarters · filed 2025-11-03 | $0.00 10-Q · filed 2025-11-03 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |